NEW YORK, March 31, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of SCYNEXIS, Inc. (NASDAQ:SCYX) who purchased shares (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey.
In particular complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SCYNEXIS’s lead product SCY-078 posed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, SCYNEXIS’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation.
Shareholders have until May 8, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/scynexis-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 



